Yonezawa Atsushi, Dutt Suparna, Chester Cariad, Kim Jeewon, Kohrt Holbrook E
Division of Oncology, Department of Medicine, Stanford University, Stanford, California. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.
Immunology and Rheumatology, Stanford University, Stanford, California.
Clin Cancer Res. 2015 Jul 15;21(14):3113-20. doi: 10.1158/1078-0432.CCR-15-0263. Epub 2015 Apr 23.
In the past 5 years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis factor receptor superfamily, represents a promising target for enhancing antitumor immune responses. CD137 helps regulate the activation of many immune cells, including CD4(+) T cells, CD8(+) T cells, dendritic cells, and natural killer cells. Recent studies indicate that the antitumor efficacy of therapeutic tumor-targeting antibodies can be augmented by the addition of agonistic antibodies targeting CD137. As ligation of CD137 provides a costimulatory signal in multiple immune cell subsets, combination therapy of CD137 antibody with therapeutic antibodies and/or vaccination has the potential to improve cancer treatment. Recently, clinical trials of combination therapies with agonistic anti-CD137 mAbs have been launched. In this review, we discuss the recent advances and clinical promise of agonistic anti-CD137 monoclonal antibody therapy.
在过去5年中，免疫调节抗体彻底改变了癌症免疫治疗。肿瘤坏死因子受体超家族成员CD137是增强抗肿瘤免疫反应的一个有前景的靶点。CD137有助于调节包括CD4(+) T细胞、CD8(+) T细胞、树突状细胞和自然杀伤细胞在内的多种免疫细胞的激活。最近的研究表明，通过添加靶向CD137的激动性抗体，可以增强治疗性肿瘤靶向抗体的抗肿瘤疗效。由于CD137的连接在多个免疫细胞亚群中提供共刺激信号，CD137抗体与治疗性抗体和/或疫苗的联合治疗有可能改善癌症治疗。最近，已开展了使用激动性抗CD137单克隆抗体进行联合治疗的临床试验。在本综述中，我们讨论激动性抗CD137单克隆抗体治疗的最新进展和临床前景。
